Alterome Therapeutics schedules first Phase 1 clinical data presentation for pan-KRAS inhibitor ALTA3263
Alterome Therapeutics will reveal first ALTA3263 Phase 1 data in November, testing the safety and early activity of its oral pan-KRAS inhibitor.
Pharma & Biotech
Pharma & Biotech
Frontier’s FMC-376 triggered responses after KRAS inhibitor failure, but can its dual-state mechanism prevent resistance?
Frontier's FMC-376 achieved a 56% response rate in 18 evaluable lung cancer patients, including prior KRAS inhibitor users. Can larger trials confirm benefit?
Pharma & Biotech
Frontier to reveal first FMC-376 clinical responses in KRAS G12C lung cancer
Frontier Medicines will present its first Phase 1 clinical findings for FMC-376 at ESMO 2026, including preliminary responses in patients previously treated with KRAS G12C inhibitors. The investigational drug targets both active and inactive KRAS G12C, but detailed response rates and patient counts remain undisclosed ahead of the presentation.
Pharma & Biotech
FDA Fast Track designation advances BH-30643 in C797S-positive lung cancer
BH-30643 gets FDA Fast Track status after early responses in C797S-positive lung cancer as BlossomHill expands the Phase 1/2 SOLARA trial.
Pharma & Biotech
Paradigm Health’s FDA collaboration puts clinical trial data automation under the spotlight
FDA review is moving closer to real time. Paradigm Health’s pilot with Amgen and AstraZeneca could reset clinical trial infrastructure.
Medical Devices & Diagnostics
Could nonthermal tumor ablation replace surgery for low-risk thyroid cancer? Pulse Biosciences launches feasibility study
Pulse Biosciences begins human study of nsPFA thyroid cancer treatment. Discover what this trial could mean for minimally invasive oncology.
Medical Devices & Diagnostics
Could Io Therapeutics’ IRX4204 reshape the science of breast cancer prevention?
Could IRX4204 help prevent triple-negative breast cancer? Discover what new RXR agonist research could mean for the future of breast cancer prevention.
Pharma & Biotech
Proton therapy delivers survival gain in head and neck cancer: Could this Lancet trial shift payer and policy resistance?
A new phase III clinical trial published in The Lancet has shown that proton therapy significantly improves overall survival and reduces treatment-related toxicities in patients with oropharyngeal cancers compared to traditional photon-based radiation. Conducted across 21 U.S. institutions and led by researchers at the University of Texas MD Anderson Cancer Center, the study is the